glp-1 news today pharma GLP-1s and the Unintended Consequences of the $100 Billion Market A harsh GLP-1 market reality:

Members receive a digitally connected scale, and employers (as well as Omada) have access to real-time data that shows how the customer is responding to GLP-1s, if a body is tolerating the medication and whether the person has been able to receive and use refills

2, the inverse probability-weighted cumulative incidence curves were somewhat overlapping in the ITT analysis, but separated in the per-protocol analysis

Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: A systematic review

Healthletic offers a 30-day satisfaction guarantee

In late July 2026 an FDA advisory committee then recommended six peptides including BPC-157, TB-500, KPV, and MOTS-c for the compounding list

doi: 10.1080/07315724.2016.1140093 134 BaeSCJungWJLeeEJYuRSungMK